Rabbit Polyclonal Antibodies Against the Calcium-Dependent Conformation of Factor IX and Their Application in Solid Phase Immunoradiometric Assays

S R Poort; I K van der Linden; C Krommenhoek-van Es; E Briët; R M Bertina

doi:10.1055/s-0038-1661461

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1986; 55(01): 122-128
DOI: 10.1055/s-0038-1661461

Original Article

Schattauer GmbH Stuttgart

Rabbit Polyclonal Antibodies Against the Calcium-Dependent Conformation of Factor IX and Their Application in Solid Phase Immunoradiometric Assays

Autoren

S R Poort

The Haemostasis and Thrombosis Research Unit, Dept, of Haematology, Leiden University Hospital, Leiden, The Netherlands
I K van der Linden

The Haemostasis and Thrombosis Research Unit, Dept, of Haematology, Leiden University Hospital, Leiden, The Netherlands
C Krommenhoek-van Es

The Haemostasis and Thrombosis Research Unit, Dept, of Haematology, Leiden University Hospital, Leiden, The Netherlands
E Briët

The Haemostasis and Thrombosis Research Unit, Dept, of Haematology, Leiden University Hospital, Leiden, The Netherlands
R M Bertina

The Haemostasis and Thrombosis Research Unit, Dept, of Haematology, Leiden University Hospital, Leiden, The Netherlands

Abstract

als PDF herunterladen

Summary

Two subpopulations of antibodies were isolated from rabbit polyclonal antiserum directed against human factor IX: one against the Ca(II)-dependent conformation of factor IX and one against the Ca(II)-independent conformation of factor IX. The two subpopulations were used for the development of immunoradiometric assays (IRMA’s) for factor IX: Ca(II)Ag and factor IX: NonCa(II)Ag respectively. Ranges for the concentration of factor IX:Ca(II)Ag and factor IX: NonCa(II)Ag were established in plasmas of healthy volunteers, patients treated with oral anticoagulants and hemophilia B patients. In the group of patients using oral anticoagulant therapy a progressively reduced ratio of factor IX:Ca(II)Ag to factor IX: NonCa(II)Ag was observed with increasing intensity of oral anticoagulant treatment. Variant factor IX molecules from hemophilia B patients . (CRM^-, CRM^Red and CRM⁺) with a defective Ca(II) binding or defective conformational transition induced by Ca(II) binding, were identified. These defects are absent in variant factor IX molecules from one hemophilia B_m patient and from patients with hemophilia B Leyden.

Key words

Factor IX antibodies - Calcium dependency - Oral anticoagulation - Hemophilia B

PDF (1482 kb)

Referenzen

References
1 Davie EW, Fujikawa K, Kurachi K, Kisiel E. The role of serine proteases in the blood coagulation cascade. Adv Enzym 1979; 48: 277-318
2 Jackson CM, Nemerson Y. Blood Coagulation. Ann Rev Biochem 1980; 49: 765-811
3 Lewis JH, Ferguson JH. Hemorrhagic diathesis due to PTC (Plasma Thromboplastin Component) deficiency. Proc Soc Exp Biol Med 1953; 82: 445-449
4 Stenflo J, Ferlund P, Egan W, Roepstorff P. Vitamin K-dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 1974; 71: 2730-2733
5 DiScipio RG, Hermodson MA, Yates SG, Davies EW. A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and proteinS. Biochemistry 1977; 16: 698-706
6 Sperling R, Furie BC, Blumenstein M, Keyt B, Furie B. Metal binding properties of γ-carboxy glutamic acid. Implications for the vitamin K-dependent blood coagulation proteins. J Biol Chem 1978; 253: 3898-3906
7 Amphlett GW, Byrne R, Castellino FJ. The binding of metal ions to bovine factor IX. J Biol Chem 1978; 253: 6774-6779
8 Amphlett GW, Kisiel W, Castellino FJ. The interaction of Ca²⁺ with human factor IX. Arch Biochem Biophys 1981; 208: 576-585
9 Reekers PP M, Lindhout MJ, Kop-Klaassen BH M, Hemker HC. Demonstration of three anomalous plasma proteins induced by a vitamin K antagonist. Biochim Biophys Acta 1973; 317: 559-562
10 Bertina RM, Veltkamp JJ. A genetic variant of factor IX with decreased capacity for Ca²⁺ binding. Brit J Haematol 1979; 42: 623-635
11 Prendergast FG, Mann KG. Differentiation of metal ion-induced transitions of prothrombin fragment 1. J Biol Chem 1977; 252: 840-850
12 Bloom JW, Mann KG. Metal ion-induced conformational transitions of prothrombin and prothrombin fragment 1. Biochemistry 1978; 17: 4430-4438
13 Furie B, Furie BC. Conformation specific antibodies as probes of the γ-carboxyglutamic acid-rich region of bovine prothrombin. Studies of metal-induced structural changes. J Biol Chem 1979; 254: 9766-9771
14 Tai MM, Furie BC, Furie B. Conformation-specific antibodies directed against the bovine prothrombin-calcium complex. J Biol Chem 1980; 255: 2790-2795
15 Lewis RM, Reisner HM, Chung KS, Roberts HR. Detection of factor IX antibodies by radioimmunoassay: effect of calcium on antibody-factor IX interaction. Blood 1980; 56: 608-614
16 Lewis RM, Reisner HM, Abels BC, Roberts HR. The effect of metal ions on human factor IX antigenicity. Thromb Haemostas 1981; 46: 137 (Abstr)
17 Briët E, Reisner HM, Roberts HR. Inhibitors in Christmas disease. In Factor VIII inhibitors Hoyer LW. (ed.). pp 123-139 Alan R. Liss, Inc; New York: 1984
18 Fantl P, Sawers RJ, Marr AG. Investigation of a haemorrhagic disease due to beta-prothromboplastin deficiency complicated by a specific inhibitor of thromboplastin formation. Austr Ann Med 1956; 5: 163-166
19 Gianelli F, Choo KH, Rees DJ G, Boyd Y, Rizza CR, Brownlee GG. Gene deletions in patients with haemophilia B and antifactor IX antibodies. Nature 1983; 303: 181-182
20 Theodorsson B, Hedner U, Nilsson IM, Kisiel W. A technique for specific removal of factor IX alloantibodies from human plasma: partial characterization of the alloantibodies. Blood 1983; 61: 973-981
21 Bertina RM, Van der Linden IK. Inhibitor neutralisation assay and electro-immunoassay of human factor IX (Christmas factor). Clin Chim Acta 1977; 77: 275-286
22 Loeliger EA, Lewis SM. Progress in laboratory control of oral anticoagulants. Lancet 1982; 2: 318-320
23 Loeliger EA, van den Besselaar AM H P, Lewis SM. Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thromb Haemostas 1985; 53: 148-154
24 Veltkamp JJ, Drion EF, Loeliger EA. Detection of the carrier state in hereditary coagulation disorders I. Thromb Diath Haemorrh 1968; 19: 279-303
25 Bertina RM, Van der Linden IK, Muller HP, Derks J, Klein-Breteler E. A monoclonal anti-human factor IX produced by a mouse hybridoma. Thromb Haemostas 1981; 46: 165 (Abstr)
26 Goodall AH, Kemble G, O’Brien DP, Rawlings E, Rotblat F, Russell GC, Janossy G, Tuddenham EG D. Preparation of factor IX deficient human plasma by immunoaffinity chromatography using a monoclonal antibody. Blood 1982; 59: 664-670
27 Mertens K, Cupers R, van Wijngaarden A, Bertina RM. Binding of human blood coagulation factor IX a and X to phospholipid membranes. Biochem J 1984; 223: 599-605
28 Fraker PJ, Speck Jr JC. Proteins and cell membrane iodinations with a sparingly soluble chloramide, l,3,4,6-tetrachloro-3a, 6a-diphenyl-glycouril. Biochem Biophys Res Commun 1978; 80: 849-857
29 Bertina RM, van Wijngaarden A, Reinalda-Poot J, Poort SR, Bom VJ J. Determination of plasma proteinS - the protein cofactor of activated protein C. Thromb Haemostas 1985; 53: 268-272
30 Briët E, Bertina RM, van Tilburg NH, Veltkamp JJ. Hemophilia B Leyden. A sex-linked hereditary disorder that improves after puberty. New Engl J Med 1982; 306: 788-790
31 Hougie C, Twomey JJ. Haemophilia Bm: a new type of factor IX deficiency. Lancet 1967; I: 698-700
32 Ørstavik KH, Laake K. Factor IX in warfarin treated patients. Thromb Res 1978; 13: 207-218
33 Fair DS, Plow EF, Edgington TS. Combined functional and immunochemical analysis of normal and abnormal human factor X. J Clin Invest 1979; 64: 884-894
34 Blanchard RA, Furie BC, Jorgensen M, Kruger SF, Furie B. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981; 305: 242-248
35 Bertina RM, van der Linden IK. Factor IX Zutphen, a genetic variant of blood coagulation factor IX with an abnormally high molecular weight. J Lab Clin Med 1982; 100: 695-704
36 Bertina RM, van der Linden IK. Factor IX Deventer - Evidence for the heterogeneity of haemophilia B_m . Thromb Haemostas 1982; 47: 136-140
37 Bertina RM, Veltkamp JJ. The abnormal factor IX of hemophilia B⁺ variants. Thromb Haemostas 1978; 40: 335-349